Alzheimer's Disease (AD)
34
9
11
15
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.9%
1 terminated out of 34 trials
93.8%
+7.2% vs benchmark
3%
1 trials in Phase 3/4
27%
4 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (34)
Adapting RDAD for DS
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
δ in Dementia Clinical Trials
Acoustic Stimulation During Sleep: Effects on Memory and p-tau217 in MCI
Evaluation of a Neuropsychological Tool to Assess Temporal Processing Abilities in Alzheimer's Disease
Social-cognitive Functioning: Validation of a New Neuropsychological Test
COGSCREEN II: Early Detection of Cognitive Impairment
Alzheimer's Disease Neuroimaging Initiative 3
Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials
Prospective Single-Arm Safety Study of Cervical LVA in AD Patients
Improv Music Therapy for Older Adults
Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease
Improvement of Sleep Disorders in Patients With Alzheimer's Disease After Sunlight Exposure Therapy.
Quantification of Hsp90 in the Human Brain
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Contribution of Pathological Alpha-synuclein as a Diagnostic Biomarker for Dementia With Lewy Bodies
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Amyloid-β Clearance Mechanisms in Alzheimer's Disease